CSL announces expansion of Illinois plasma therapy manufacturing facility

CSL announced a $1.5 billion expansion of its plasma therapy manufacturing facility in Kankakee, Illinois, expected to be operational by 2031. The expansion will create at least 300 new jobs and incorporate advanced Horizon 2 manufacturing technology to increase production efficiency of plasma-derived therapies. This investment builds on over $3 billion already spent on U.S. operations since 2018.

03/09/2026, 11:01 AM • Benzinga

Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract

CSL Seqirus has secured a new contract with Canada's Public Health Agency of Canada (PHAC) to supply millions of doses of cell-based adjuvanted influenza vaccines in the event of a WHO-declared pandemic. The agreement replaces a previous egg-based vaccine contract and leverages CSL Seqirus's proven cell-based manufacturing technology, which offers improved scalability and rapid production capabilities.

03/06/2026, 12:59 PM • Benzinga

Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo

Eli Lilly announced positive Phase 3b trial results for the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) in treating plaque psoriasis and obesity. The combo achieved 27.1% complete skin clearance with 10% weight loss versus 5.8% for Taltz alone, representing a 40% relative improvement. Additionally, Eli Lilly entered an exclusive licensing agreement with CSL for clazakizumab development.

02/18/2026, 12:51 PM • Benzinga

Global Fibrin Sealant Market Size to Reach USD 3.57 Billion by 2035 with 8.37% CAGR – SNS Insider

The global fibrin sealant market is projected to grow from USD 1.60 billion in 2025 to USD 3.57 billion by 2035 at a CAGR of 8.37%, driven by increasing surgical volumes, minimally invasive procedures, and expanding applications in trauma and wound care. However, high costs and insurance coverage limitations remain barriers to adoption in emerging markets.

02/17/2026, 3:51 AM • GlobeNewswire

VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization

VarmX and Rentschler Biopharma expanded their collaboration to manufacture VMX-C001, a novel coagulation therapy, for Phase 3 development and commercialization. The drug, which restores blood coagulation in patients on FXa DOACs requiring urgent surgery, has received FDA Fast Track Designation and PMDA Phase 1 waiver. Manufacturing will transition from Laupheim, Germany to Milford, MA, with Phase 3 trials expected to begin in early 2026.

01/08/2026, 7:00 AM • GlobeNewswire

CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)

CSL's Broadmeadows facility was recognized as the Overall Winner of the 2025 Facility of the Year Award by ISPE, showcasing advanced automation, sustainable design, and a nine-fold increase in plasma processing capacity.

10/26/2025, 10:30 PM • Benzinga

Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines

A recent real-world evidence study reveals that cell-based quadrivalent influenza vaccines provide 19.8% greater protection against test-confirmed influenza compared to standard egg-based vaccines for populations aged six months to 64 years.

10/21/2025, 8:30 AM • Benzinga

ヴァルムエックス (VarmX)、日本の規制当局である医薬品医療機器総合機構 (PMDA) からリード資産VMX-C001に対する第I相試験免除を取得

VarmX, a biotechnology company, received an exceptional exemption from Japan's PMDA for Phase I trials of VMX-C001, a novel bypass drug for patients on FXa inhibitors. This allows direct entry into Phase III global trials and potentially accelerates drug development and market access in Japan.

09/25/2025, 2:10 AM • GlobeNewswire

VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001

VarmX has been granted a rare Phase 1 waiver by the Japanese PMDA for its lead asset VMX-C001, allowing direct entry into Phase 3 clinical trials. This waiver recognizes the global dataset and enables inclusion of Japanese patients in the global EquilibriX-S study for a novel factor Xa direct oral anticoagulant (FXa DOAC) bypass agent.

09/25/2025, 2:10 AM • GlobeNewswire

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

The FDA approved Ionis Pharmaceuticals' Dawnzera, the first RNA-targeted medicine for preventing hereditary angioedema (HAE) attacks in patients 12 and older, demonstrating significant attack rate reduction in clinical trials.

08/21/2025, 2:24 PM • Benzinga

Valneva annonce un accord exclusif avec CSL Seqirus pour le marketing et la distribution de ses vaccins en Allemagne

Valneva has signed an exclusive agreement with CSL Seqirus for marketing and distributing its three commercial vaccines in Germany, starting July 2025 for the chikungunya vaccine and January 2026 for Japanese encephalitis and cholera/ETEC vaccines.

06/26/2025, 1:00 AM • GlobeNewswire

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

Valneva signed an exclusive agreement with CSL Seqirus for marketing and distributing three proprietary vaccines in Germany, starting July 2025 for chikungunya vaccine and January 2026 for Japanese Encephalitis and cholera/ETEC vaccines.

06/26/2025, 1:00 AM • GlobeNewswire